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The Influence of Safety, Efficacy, and Medical Condition Severity on
Natural v. Synthetic Drug Preference
Abstract
Research indicates that there is a preference for natural v. synthetic products, but the influence of this
preference on drug choice in the medical domain is largely unknown. We present 5 studies in which
participants were asked to consider a hypothetical situation in which they had a medical issue requiring
pharmacological therapy. Participants ( N = 1223) were asked to select a natural, plant-derived, or synthetic
drug. In studies 1a and 1b, approximately 79% of participants selected the natural v. synthetic drug, even
though the safety and efficacy of the drugs were identical. Furthermore, participants rated the natural drug as
safer than the synthetic drug, and as that difference increased, the odds of choosing the natural over synthetic
drug increased. In studies 2 and 3, approximately 20% of participants selected the natural drug even when they
were informed that it was less safe (study 2) or less effective (study 3) than the synthetic drug. Finally, in study
4, approximately 65% of participants chose a natural over synthetic drug regardless of the severity of a specific
medical condition (mild v. severe hypertension), and this choice was predicted by perceived safety and
efficacy differences. Overall, these data indicate that there is a bias for natural over synthetic drugs. This bias
could have implications for drug choice and usage.
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The Influence of Safety, Efficacy,
and Medical Condition Severity on
Natural v. Synthetic Drug Preference
Brian P. Meier, PhD, Courtney M. Lappas, PhD
Research indicates that there is a preference for natural v.
synthetic products, but the influence of this preference on
drug choice in the medical domain is largely unknown.
We present 5 studies in which participants were asked to
consider a hypothetical situation in which they had a med-
ical issue requiring pharmacological therapy. Participants
(N = 1223) were asked to select a natural, plant-derived, or
synthetic drug. In studies 1a and 1b, approximately 79%
of participants selected the natural v. synthetic drug,
even though the safety and efficacy of the drugs were iden-
tical. Furthermore, participants rated the natural drug as
safer than the synthetic drug, and as that difference
increased, the odds of choosing the natural over synthetic
drug increased. In studies 2 and 3, approximately 20% of
participants selected the natural drug even when they
were informed that it was less safe (study 2) or less effec-
tive (study 3) than the synthetic drug. Finally, in study 4,
approximately 65% of participants chose a natural over
synthetic drug regardless of the severity of a specific med-
ical condition (mild v. severe hypertension), and this
choice was predicted by perceived safety and efficacy
differences. Overall, these data indicate that there is
a bias for natural over synthetic drugs. This bias could
have implications for drug choice and usage. Key words:
heuristics and biases; cognitive psychology; affect and
emotion. (Med Decis Making XXXX;XX:xx–xx)
Food and drug companies use terms such as nat-ural or nature in their names and marketing ma-
terials. For example, people can buy Applegate’s
Natural Beef Hot Dogs, Truvia’s Natural Sweeteners,
and vitamins made by companies such as Nature
Made, Nature’s Way, or Natural Vitality. Manufac-
turers likely use terms related to natural because
people seem to assume that natural products are
preferable to unnatural, synthetic, or artificial pro-
ducts1–4 and will pay a premium price for them.
Indeed, Rozin and others3 showed that people prefer
food and therapeutic drugs when they are described
as natural rather than processed or human made,
and Lynch and Berry2 showed that people perceive
herbal medicines to be safer than prescribed conven-
tional medicines.
Rozin and colleagues3,5 theorized that natural v.
synthetic preferences are driven by our evolutionary
history, which involved an intimate connection
with the natural world. In other words, there may
be an innate preference for the natural world because
of evolutionary pressures and our ancestors’ interac-
tions with and dependence on nature. Wilson6 used
the term biophilia to describe this theory. Research
has supported this basic theory of human preference
in a number of ways. For example, Rozin and others7
showed that the preference for natural is cross-
cultural. In 6 countries, it was shown that people
have positive free associations to the term natural
and have negative views of genetic engineering.
Such cross-cultural findings are typically suggestive
of a universal pattern of behavior. In more general
terms, researchers have shown that people who
spend time in amore natural (e.g., a park) v.manmade
(e.g., a city’s downtown area) setting had improve-
ments in cognitive functioning and affective states.8,9
Although a natural bias may exist because of our
evolutionary history, it may also exist because of
experiences in everyday life in which natural
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products are often presented in advertisements,
social media, newsletters, and the blogosphere as
more positive than their synthetic counterparts.
These experiences, as well as positive personal inter-
actionswith natural products, may create and sustain
a cognitive heuristic suggesting that ‘‘natural is bet-
ter.’’4 In sum, a preference for natural things may
have originated as a result of the adaptive pressures
in our evolutionary history and/or as a result of per-
sonal experiences.
Rozinandcolleagues3,5,7 haveconductedanumber
of studies that have examined the extent of a seem-
ingly innate preference for natural things. Across
a variety of items, they contend that their research
shows that a preference for natural items is driven
by instrumental and ideational factors. Instrumental
factors focus on the specific attributes of an item
(e.g., a natural product is healthier or safer), whereas
ideational factors focus on the inherent appeal of nat-
ural items, such as the idea that they are morally bet-
ter. Li and Chapman4 find that instrumental and
ideational reasons for choosing natural over synthetic
items are closely connected.
Although there is research on natural preferences
for foods and drugs, we are unaware of research that
has examined natural v. synthetic drug choices
involving personal medical issues. This area is
undoubtedly important given that individuals rou-
tinely make health care choices, and natural drug
products are frequently available. A study of 35,000
Americans on complementary health approaches
revealed that nearly 1 in 5 individuals reported using
natural health supplements other than vitamins and
minerals.10 This usage rate suggests that people find
value in natural drug products but does not address
if they are biased in choosing natural over synthetic
drugs in decisions related to medical issues even
when such decisions may not be beneficial.
It is likely that part of the potential appeal of natu-
ral drugs could come from the perception that they
are safer than their synthetic counterparts.2 People
worry about the adverse side effects of prescribed
medication (typically synthetic), and these concerns
mayprevent themfromadhering toapharmacological
treatment regimen.11,12 Such worries may not be as
prevalent with natural drugs. However, despite the
appeal and use of natural products, it may be inaccu-
rate to assume that all naturally derived drugs are
safer and/or better than synthetic products. Indeed,
some of the most toxic substances known to human-
kind are natural rather than synthetic (e.g., botulinum
toxins, ricin, and arsenic13–15). Furthermore, many
herbal or natural drugs either have not been
thoroughly tested for safety and efficacy or have
been shown to possess significant toxicities.16–18
For example, ginkgo biloba and aloe vera extracts
have been shown to be carcinogenic, and Chinese
green tea extracts have been identified as a cause of
severe hepatotoxicity.19,20 Although some natural
drugs and products possess beneficial properties,
it may be inappropriate21 to assume that anything
labeled natural is safe and effective. Yet,wepredicted
that in the context of personal medical issues, natural
drugs would be preferred over synthetic counterparts
given the bias for natural things.
OVERVIEW OF STUDIES
In 5 studies, we sought to examine natural v. syn-
thetic drug choices in medical decision making by
focusing on issues related to safety, efficacy, and
medical condition severity. In studies 1a and 1b, we
examined preference for, and safety ratings of, a natu-
ral v. a synthetic drug when both the safety and effi-
cacy of the 2 drugs were identical. In studies 2 and
3, we examined a preference for a natural v. a syn-
thetic drug when the natural drug was either less
safe (study 2) or less effective (study 3) than the syn-
thetic drug. In study 4, we examined a preference for,
and safety and effectiveness ratings of, a natural v.
a synthetic drug for a mild v. a severe medical condi-
tion. In all studies, we predicted that participants
would exhibit a preference for natural over synthetic
drugs and that this bias might be present in some par-
ticipants even when the natural drugs are described
as being less safe and/or less effective. Furthermore,
prior research on natural v. synthetic products such
as vitamins or herbal medicines2,4 led us to predict
that perceived safety and efficacy would be related
to a natural drug bias.
STUDIES 1A AND 1B
Methods
Study 1a participants
Participants in studies 1a and 2 to 4 came from
Amazon’s Mechanical Turk (MTurk), a crowdsourc-
ing site with over 500,000 individuals. Participants
fromMTurk have been shown to bemore demograph-
ically diverse than typical college student samples
and to produce data as reliable as laboratory-based
data.22 We recruited people living in the United
States who were 18 years of age or older (using
MTurk’s participant selection options). Participants
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in these studieswere paid $.20 for their participation.
Study 1a participants were 210 individuals (123
males, 84 females, 3 no report) with a mean (SD) age
of 31.40 (10.74) years. The majority of the sample
was Caucasian (153 or 73%).
Study 1b participants
To ensure that the results fromMTurkwere similar
to the results of an in-person study, we recruited par-
ticipants from the Gettysburg College community
(i.e., people walking on campus). Study 1b partici-
pants were given a candy bar to complete the study.
We recruited 83 individuals (26 males, 56 females,
1 intergender) with a mean (SD) age of 28.49 (12.99)
years. The majority of the sample was Caucasian (71
or 86%). Two participants were eliminated from the
study because they did not answer the choice
question.
Participants in all studies first gave informed con-
sent. Participants were told that researchers were
interested in their judgments and perceptions about
common things such as drugs. They were asked to
‘‘Imagine that your doctor tells you that you have
a medical issue that requires you to take a drug. You
have to choose between one of the two options shown
below.’’ Participants were presented with 2 options:
 Option 1 is a synthetic drug created in the laboratory
by scientists. Studies have been conducted on this
drug for 20 years. It has been shown to be effective
in 85% of users. The drug has also been shown to
cause mild side effects on rare occasions and serious
side effects in .5% of users.
 Option 2 is a natural drug taken from a common plant.
Studies have been conducted on this drug for 20 years.
It has been shown to be effective in 85% of users. The
drug has also been shown to causemild side effects on
rare occasions and serious side effects in .5% of users.
The options were identical in terms of safety (serious
side effects in .5% of users) and efficacy (effective in
85%of users), but onewas described as synthetic and
the other one as natural. After choosing one option,
participants were asked to rate the safety of each
drug by choosing one number from a scale (1 = not
at all safe, 5 = moderately safe, 9 = very safe). Partic-
ipants then completed demographic questions and
were debriefed.
Results and Discussion
Because the natural and synthetic drugs were
equally effective and safe, an unbiased findingwould
be one in which participants chose the drugs at an
equal rate (50% for each drug) and perceived the
drugs as similarly safe. However, we predicted
a bias for natural drugs in terms of choice and safety.
As shown in Figure 1, participants selected the natu-
ral (study 1a: 166 of 210 or 79% of participants; study
1b: 64 of 81 or 79% of participants) as opposed to the
synthetic drug at a rate that was statistically different
than 50%: study 1a, x2 (1, N = 210) = 70.88, P\ .05,
Cramer’s phi = .58; study 1b, x2 (1, N = 81) = 22.27,
P\ .05, Cramer’s phi = .52.
In terms of perceived safety, participants rated the
natural drug as significantly safer (study 1a:M = 7.05,
SD = 1.37; study 1b:M = 7.25, SD = 1.30) than the syn-
thetic drug (study 1a:M = 6.29, SD = 1.88; study 1b:M
= 6.73, SD = 1.43), study 1a: t(208) = 6.21, P\ .05, d =
.43; study 1b: t(80) = 3.94, P\ .05, d = .44. (Note: In
study 1a, 1 participant skipped the safety ratings.)
Although participants perceived the natural drug as
safer than the synthetic drug, we do not know if this
difference predicts or is related to drug choice. To
examine this question, we computed difference
scores by subtracting the synthetic drug rating from
the natural drug rating. Positive scores mean that
participants rated the natural drug as safer than the
synthetic drug, and negative scores mean that partic-
ipants rated the synthetic drug as safer than the natu-
ral drug. We used these difference scores to predict
drug choice (synthetic = 1; natural = 2) in a logistics
regression analysis. In both studies, we found that
the difference score was a positive and significant
predictor of drug choice: study 1a, Nagelkerke R2 =
.26, B = 1.15, SE = .27, Wald (df = 1) = 18.03, P\
.05, odds ratio = 3.16 (95% confidence interval [CI]
= 1.86, 5.38); study 1b, Nagelkerke R2 = .26, B =
1.31, SE = .48,Wald (df = 1) = 7.29, P\ .01, odds ratio
= 3.70 (95% CI = 1.43, 9.56).
Overall, when faced with a medical issue, partici-
pants chose a natural over a synthetic drug when
safety and efficacy were identical. Furthermore, on
average, participants believed that the natural drug
was safer than the synthetic drug, and as that differ-
ence increased or became more positive, the odds of
choosing the natural over the synthetic drug
increases as well. Such results suggest that perceived
safety plays a role in a natural drug bias.
STUDY 2
In study 2, we examined natural v. synthetic drug
choicewhen safety varied.Weexpected that somepar-
ticipants would still choose the natural drug over the
synthetic drug evenwhen itwas described as less safe.
NATURAL VERSUS SYNTHETIC DRUG PREFERENCE
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Methods
Participants were 269 individuals (152 males, 116
females, 1 no report) from MTurk with a mean (SD)
age of 30.78 (9.20) years. Our original sample
included 326 participants, but we eliminated 57 par-
ticipants who already completed study 1a or did not
complete study questions (i.e., they started the study
but dropped out before answering questions). The
majority of the sample was Caucasian (205 or 76%).
As in study 1, participants were told that research-
ers were interested in their judgments and per-
ceptions about common things such as drugs.
Participants were randomly assigned to 1 of 2 condi-
tions. In both conditions, they were asked to imagine
the same scenario from studies 1a and 1b, but in con-
dition 1, 2 synthetic drugs were presented, one with
serious side effects in .5% of users and one with seri-
ous side effects in 1% of users. In condition 2, the
drug with 1% of serious side effects was described
as a natural drug and the one with .5% of serious
side effects was a synthetic drug. Effectiveness was
the same in both conditions (85%). After selecting
one option, participants completed demographic
questions and were debriefed.
Results and Discussion
As shown in Figure 2, only 14%, or 17 of 126, par-
ticipants in condition 1 chose the drugwith a 1% rate
of serious side effects, whereas 36%, or 52 of 143,
participants in condition 2 chose the drug with
a 1% rate of serious side effects when it was labeled
natural, a significant difference, x2 (1, N = 269) =
18.37, P\ .05, Cramer’s phi = .26.
In condition 1, inwhich both drugswere described
as synthetic, some participants selected the less safe
drug. This was possibly due to a misunderstanding
of risk data or a less than careful reading of safety
information, which is not surprising given that
some people seem to have difficulty understanding
risk.23 Nonetheless, the natural label increased the
percentage of participants who preferred the less
safe drug in condition 2 (almost 3 times higher), sug-
gesting that in some individuals, the strength of the
natural bias may influence safety perception enough
to override increased risk.
STUDY 3
In study 3, we focused on drug effectiveness rather
than safety. We again predicted that some partici-
pants would choose the natural drug over the syn-
thetic drug even when it was described as less
effective.
Methods
Participants were 273 individuals (167 males, 105
females, 1 no report) fromMturkwith amean (SD) age
of 30.93 (10.90) years. Our original sample included
Figure 1 Frequency of drug choice in studies 1a and 1b.
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394 participants, but we eliminated 121 participants
who already completed studies 1a or 2 or did not
complete the study questions (i.e., they started the
study but dropped out before answering questions).
The majority of the sample was Caucasian (201 or
74%).
Participants were again told that researchers were
interested in their judgments andperceptions of com-
mon things such as drugs, and they were asked to
imagine the situation from previous studies in 1 of 2
randomly assigned conditions. In condition 1, 2 syn-
thetic drugs were presented, one that was effective
in 85% of users and one that was effective in 70%
of users. In condition 2, the drug that was effective
in 70% of users was natural, and the drug that was
effective in 85% of users was synthetic. Safety was
the same in both conditions (serious side effects in
.5% of users). After selecting one option, partici-
pants completed demographic questions and were
debriefed.
Results and Discussion
As shown in Figure 3, 0 of 144 participants in con-
dition 1 selected the drug with a 70% effectiveness
rate, whereas 19%, or 24 of 129, participants in
condition 2 selected the drug with a 70% effective-
ness rate when it was labeled natural, a significant
difference, x2 (1, N = 273) = 29.37, P\ .05, Cramer’s
phi = .33.
Overall, participants preferred a more effective
drug when safety was held constant. Yet, a natural
label significantly increased the percentage of partic-
ipants who preferred the less effective drug.
STUDY 4
In our final study, we examined a potential con-
found aswell as a potentialmoderator, andwe further
examined the impact of safety and efficacy on drug
preference. In prior studies, the scenarios involved
a doctor telling participants to select a natural v. syn-
thetic drug,which couldhave artificially inflated nat-
ural drug choices because the doctor’s status may
have legitimized the natural drug. We eliminated
any reference to a doctor in study 4. Also, in prior
studies, the scenarios asked participants to imagine
they had a ‘‘medical issue,’’ which may have been
too vague for participants to fully understand their
drug choice. In study 4, we asked participants to con-
sider a scenario in which they had either mild or
severe hypertension. This change allowedus to deter-
mine if a natural drug bias is eliminated when an
actualmedical issue is considered and/orwhenacon-
dition is mild v. severe. Finally, we eliminated any
mention of safety and efficacy data and asked partic-
ipants to rate the safety and effectiveness of each
drug. Such ratings allowed us to determine if safety
and efficacy perceptions play a role in drug choice
when no information about these parameters is given.
We expected to find a natural drug preference as well
as higher safety ratings for the natural v. synthetic
drug. In terms of effectiveness, it has been shown
Figure 2 Frequency of drug choice by condition in study 2.
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that people perceive herbal drugs to be less effective
than prescribed drugs,2 which suggested that the syn-
thetic drug might be rated by participants as more
effective than the natural drug.
Methods
Participants were 390 individuals (199 males, 185
females, 3 intergender, 3 no report) from Mturk with
a mean (SD) age of 31.99 (10.58) years. Our original
sample included 403 participants, but we eliminated
13 participants who had already completed studies
1a, 2, or 3 or did not complete the study questions
(i.e., they started the study but dropped out before
answering questions). Our elimination rate is smaller
because we programed the study in a way that
allowed us to eliminate prior participants before
they started the study. The majority of the sample
was Caucasian (301 or 77%).
We first chose a common medical issue, hyperten-
sion. We used hypertension (high blood pressure)
because it is a condition that people are undoubtedly
aware of given that blood pressure is measured rou-
tinely at medical offices. We wanted to examine
amild v. severemedical issue sowe usedmild hyper-
tension (mild high blood pressure) and severe hyper-
tension (severe hypertension). Todetermine if people
actually perceive the seriousness of these conditions
to differ, we randomly assigned 25 individuals not
involved in the other studies to rate the seriousness
of either mild hypertension (mild high blood
pressure) or severe hypertension (severe high blood
pressure) using a 9-point scale (1 = not at all serious,
5 =moderately serious, 9 = very serious). Participants
rated severe hypertension (M = 7.90, SD = 1.10) as
a more serious medical condition than mild hyper-
tension (M = 5.20, SD = 1.52), t(23) = 4.82, P\ .05,
d = 2.04.
Participants were randomly assigned to 1 of 2 con-
ditions, and theywere told to ‘‘Imagine that you learn
that you have mild hypertension (mild high blood
pressure) [condition 1] or severe hypertension
(severe high blood pressure) [condition 2] and you
need to take a drug to treat it. You have to choose
between one of the two options shown below.’’ In
both conditions, the options from the prior studies
were given: option 1 is a synthetic drug created in
the laboratory by scientists, and option 2 is a natural
drug taken from a common plant. After choosing one
option, participants were asked to rate the safety (1 =
not at all safe, 5 = moderately safe, 9 = very safe) and
effectiveness (1 = not at all effective, 5 = moderately
effective, 9 = very effective) of each drug. Participants
then completed demographic questions and were
debriefed.
Results and Discussion
We first determined if the natural v. synthetic drug
choice differed between conditions. As shown in Fig-
ure 4, 65%, or 121 of 186, participants in the mild
hypertension condition and 63%, or 129 of 204,
Figure 3 Frequency of drug choice by condition in study 3.
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participants in the severe hypertension condition
selected the natural drug. These rates were not signif-
icantly different, x2\1. Overall, though, a significant
majority of people (higher than 50%) selected the nat-
ural v. synthetic drug, x2 (1,N = 390) = 31.03, P\ .05,
Cramer’s phi = .28.
We next examined safety ratings for each drug type
by conditionusing a 2 (rating type: natural drug rating
v. synthetic drug rating) by 2 (condition: mild hyper-
tension v. severe hypertension) mixed-model analy-
sis of variance (ANOVA). The main effect of rating
typewas significant, F(1, 388) = 60.42, P\ .05, partial
eta squared = .14. Participants rated the natural drug
as safer (M = 6.49, SD = 1.70) than the synthetic drug
(M = 5.45, SD = 2.01) regardless of condition. The
main effect of condition and the interaction between
condition and rating type were not significant, Fs\
1.40.
We next examined effectiveness ratings for each
drug type by condition using a 2 (rating type: natural
drug rating v. synthetic drug rating) by 2 (condition:
mild hypertension v. severe hypertension) mixed-
model ANOVA. The main effect of rating type was
significant, F(1, 388) = 75.28, P \ .05, partial eta
squared = .16. Participants rated the natural drug as
less effective (M = 5.85; SD = 1.62) than the synthetic
drug (M = 6.83; SD = 1.69) regardless of condition.
The main effect of condition and the interaction
between condition and rating type were not signifi-
cant, Fs\ 1.70.
To determine if safety and effectiveness difference
scores were related to drug choice, we computed 2
difference scores by subtracting the synthetic drug
rating from the natural drug rating. Positive scores
mean that participants rated the natural drug as safer
or as more effective than the synthetic drug, and neg-
ative scores mean the reverse. We collapsed across
condition given that we did not find differences in
choice, safety, or effectiveness by condition severity.
We then used a logistic regression analysis to predict
drug choice by safety and effectiveness rating differ-
ence scores in the same model. We found that more
positive safety and effectiveness rating difference
scores were significantly predictive of a natural v.
synthetic drug choice: safety, B = 1.15, SE = .16,
Wald (df = 1) = 55.34, P \ .05, odds ratio = 3.17
(95% CI = 2.34, 4.29); effectiveness, B = 1.02, SE =
.14, Wald (df = 1) = 50.68, P\ .05, odds ratio = 2.77
(95% CI = 2.09, 3.66). The overall Nagelkerke R2 for
the model was .72.
There were a number of noteworthy findings in
study 4. Overall, participants preferred a natural v.
a synthetic drug to treat hypertension regardless of
its severity and without the potential legitimizing
effect of a doctor. Furthermore, on average, partici-
pants believed the natural drug was safer than the
synthetic drug, and as that difference increased, or
becamemore positive, the odds of choosing the natu-
ral over synthetic drug increased. Participants also
believed the natural drug was less effective than the
Figure 4 Frequency of drug choice by condition in study 4.
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synthetic drug (a negative difference score), but as
that difference score decreased, or became more pos-
itive, the odds of choosing the natural drug over the
synthetic drug increased.
GENERAL DISCUSSION
The results of 5 studies reveal that participants
were biased toward a natural drug label. In studies
1a and 1b, participants preferred a natural v. a syn-
thetic drug and rated the natural drug as safer even
though safety and efficacy were identical. Further-
more, more positive safety rating difference scores
(natural rating minus synthetic rating) increased the
odds of a natural drug choice. In studies 2 and 3, com-
pared to a control condition, approximately 1 in 5
participants reported that they would take a natural
drug even when it was presented as less safe or less
effective than a synthetic drug. Finally, in study 4,
using a scenario that did not mention a doctor, safety,
or efficacy, approximately 65% of people chose a nat-
ural over a synthetic drug regardless of the severity of
a specific medical issue (hypertension), and per-
ceived safety and effectiveness difference scores pre-
dicted this choice.
The results of our studies conceptually replicate
and extend past work.2–4 They conceptually replicate
past work in showing that participants have a bias for
natural over synthetic products. They extend past
work in showing that such biases occurred in the con-
text of personal medical issues and are predicted by
safety and effectiveness ratings. Study 4 was particu-
larly informative as it showed that participants rated
a natural drug as safer but less effective than a syn-
thetic drug, yet the majority still chose it regardless
of the severity of hypertension. This study reveals
that some participantsmay bewilling to sacrifice effi-
cacy to take a natural as opposed to a synthetic drug.
Such findings suggest that theories related to bio-
philia6 and a ‘‘natural is better’’ heuristic4 may have
merit. Although it may be difficult to measure the rel-
ative contribution of each of these 2 theories to the
natural drug preference, future work could investi-
gate the extent to which a natural drug bias is related
to a general ‘‘natural is better’’ tendency. For exam-
ple, it will be telling in future studies to examine
the extent to which people who choose a natural
drug over a synthetic drug in a medical context also
choose other, nondrug, natural products over their
synthetic counterparts.
The current findings have potential implications
in clinical domains. It may be that a natural drug
bias could result in some individuals making detri-
mental medical decisions, such as choosing to take
a drug described as natural that may not have been
tested for safety and efficacy. However, there are
also likely to be positive aspects of the current bias
when considering clinical settings. If a natural drug
is tested for safety and efficacy, it is possible that
some individuals would be more likely to adhere to
a pharmacological regimen when taking it because
they believe it is safer than a synthetic drug. Indeed,
one reason for a lack of adherence to a pharmacologi-
cal regimen is a fear of adverse side effects.11,12 Med-
ical doctors could therefore use a natural drug bias to
the advantage of their patients by informing them,
when possible, that a prescribed drug is natural or
almost identical to a natural compound, which may
increase adherence behavior.
Our studies are not without limitations. One limi-
tation relates to the hypothetical situations used in all
of the studies. The use of this paradigm does not
allow us to determine if participants’ actual behavior
would match their intentions, as we know that inten-
tions do not always equal behavior in a one-to-one
fashion.24 Archival studies and creative laboratory
studies could examine the natural drug bias in actual
behavioral settings. For example, in a behavioral lab-
oratory setting, researchers could offer participants
a choice of an ostensible thank you gift in the form
of a free trial of a nonprescription pain reliever that
is described as being of either natural or synthetic ori-
gin. The current resultswould lead one to predict that
the natural optionwould be selectedmore frequently,
which would lend considerable credibility to the
hypothetical results of the current studies.
A second potential limitation relates to the medi-
cal condition of interest. Although our data indicate
that a natural drug preference is apparent in hypo-
thetical situations involving a general medical condi-
tion, as well as a mild v. severe specific medical
condition (hypertension), we have not shown that
this bias is apparent in a variety of medical condi-
tions. It might be that in situations that could result
in impending death (e.g., cancer, heart disease, or
serious infections), a natural drug bias would disap-
pear in favor of a synthetic drug bias given that partic-
ipants in study 4 rated the synthetic drug as more
effective. Additional research will be informative in
examining this possibility.
Future work will be needed to further test the
underlying theory or theories related to a natural
drug bias as well as the potential clinical and behav-
ioral significance of such a bias. The current results
and prior work suggest that a natural label may have
MEIER, LAPPAS
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interesting consequences for behavior and beliefs in
the medical context involving drug choice.
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